US OptionsDetailed Quotes
VNDA250117C5000
- 0.20
- +0.02+11.11%
15min DelayClose Dec 31 16:00 ET
0.20High0.13Low
0.20Open0.18Pre Close26 Volume837 Open Interest5.00Strike Price389.00Turnover57.95%IV8.56%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.3910Delta0.6598Gamma31.93Leverage Ratio-0.0073Theta0.0008Rho12.49Eff Leverage0.0039Vega
Vanda Pharmaceuticals Stock Discussion
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals (VNDA) has received FDA Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor designed to treat polycythemia vera (PV). PV is a rare blood cancer affecting approximately 1 in 2000 Americans, characterized by excessive red...
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals confirmed receipt of a second unsolicited, non-binding proposal from Cycle Group Holdings to acquire the company for $8.00 per share in cash. This proposal, received on September 23, 2024, is economically identical to the previously rejected offer from May 24, 2024.
Vanda's Board of Directors unanimously dete...
No comment yet